Cantor Fitzgerald Weighs in on Editas Medicine FY2026 Earnings

Editas Medicine, Inc. (NASDAQ:EDITFree Report) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Editas Medicine in a report released on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earnings of ($0.89) per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Editas Medicine’s current full-year earnings is ($2.71) per share.

Editas Medicine (NASDAQ:EDITGet Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.08. The firm had revenue of $4.66 million for the quarter, compared to the consensus estimate of $0.79 million. Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. During the same quarter in the previous year, the company posted ($76.00) EPS.

Other equities analysts also recently issued research reports about the company. HC Wainwright started coverage on Editas Medicine in a research report on Monday, April 28th. They set a “buy” rating and a $3.00 target price on the stock. Wall Street Zen raised Editas Medicine from a “sell” rating to a “hold” rating in a research report on Wednesday, May 14th. Finally, Robert W. Baird cut their price objective on Editas Medicine from $8.00 to $4.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 13th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Editas Medicine currently has a consensus rating of “Hold” and a consensus target price of $5.36.

View Our Latest Stock Analysis on EDIT

Editas Medicine Stock Performance

NASDAQ EDIT opened at $2.03 on Tuesday. The company has a market cap of $169.94 million, a P/E ratio of -0.79 and a beta of 2.10. The business’s 50 day moving average price is $1.52 and its 200-day moving average price is $1.52. Editas Medicine has a fifty-two week low of $0.91 and a fifty-two week high of $6.22.

Institutional Investors Weigh In On Editas Medicine

A number of hedge funds have recently made changes to their positions in EDIT. SG Americas Securities LLC lifted its stake in shares of Editas Medicine by 103.7% during the 4th quarter. SG Americas Securities LLC now owns 81,669 shares of the company’s stock worth $104,000 after purchasing an additional 41,573 shares during the last quarter. Ieq Capital LLC acquired a new stake in Editas Medicine during the fourth quarter worth about $31,000. Raymond James Financial Inc. purchased a new position in Editas Medicine during the fourth quarter worth approximately $303,000. Monaco Asset Management SAM purchased a new position in Editas Medicine during the fourth quarter worth approximately $1,359,000. Finally, Intech Investment Management LLC lifted its position in shares of Editas Medicine by 43.1% in the fourth quarter. Intech Investment Management LLC now owns 40,942 shares of the company’s stock valued at $52,000 after acquiring an additional 12,336 shares in the last quarter. 71.90% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Gilmore Neil O’neill sold 15,192 shares of the company’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $1.72, for a total transaction of $26,130.24. Following the completion of the sale, the chief executive officer now directly owns 280,282 shares in the company, valued at $482,085.04. This represents a 5.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. In the last ninety days, insiders sold 16,364 shares of company stock worth $28,146. 2.10% of the stock is currently owned by company insiders.

Editas Medicine Company Profile

(Get Free Report)

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.

Featured Stories

Earnings History and Estimates for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.